The increasing number and availability of chemotherapeutic and biologic agents that merit testing in multiple sclerosis (MS) has highlighted the need to coordinate planning among medical centers and agree on systems of assessing clinical change, as pointed out previously by Brown et al.1 This report provides a brief overview of some of the current methods of functional assessment and suggests that though investigators at different centers may adapt scoring techniques to their special interests, multicenter collaboration will be enhanced by the inclusion of a core system assuring aggregation of comparable information on the largest possible number of patients.
Sibley2 described three categories of therapeutic agents: (1) completely effective agents that halt progress and reverse signs and symptoms partially or completely, (2) completely ineffective agents that are associated with considerable improvement because of placebo responses, particularly in early stages of the disease, and (3) partially effective agents in which
Slater RJ. Scoring Techniques and Problems in the Evaluation of Change in Patients. Arch Neurol. 1983;40(11):675–677. doi:10.1001/archneur.1983.04050100015005
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: